Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Emerging Infectious Diseases|December 12, 2023
Macacine alphaherpesvirus 1 (B Virus) Infection in Humans, Japan, 2019Souichi Yamada, Harutaka Katano, Yuko Sato, et al.
Molecular Pain|December 14, 2021
Heparan sulfate 3-<i>O</i>-sulfotransferase 4 is genetically associated with herpes zoster and enhances varicella-zoster virus-mediated fusogenic activitySeii Ohka, Souichi Yamada, Daisuke Nishizawa, et al.
Plos One|October 8, 2019
Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in miceHirofumi Kato, Mutsuyo Takayama-Ito, Itoe Iizuka-Shiota, et al.
Journal of Virology|January 12, 2023
Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected HamstersNozomi Shiwa-Sudo, Yusuke Sakai, Naoko Iwata-Yoshikawa, et al.
Iscience|January 23, 2023
Non-Omicron breakthrough infection with higher viral load and longer vaccination-infection interval improves SARS-CoV-2 BA.4/5 neutralizationSho Miyamoto, Takeshi Arashiro, Akira Ueno, et al.
Viruses|August 26, 2022
Susceptibility of Type I Interferon Receptor Knock-Out Mice to Heartland Bandavirus (HRTV) Infection and Efficacy of Favipiravir and Ribavirin in the Treatment of the Mice Infected with HRTVHikaru Fujii, Hideki Tani, Kazutaka Egawa, et al.
Virus Research|December 14, 2023
Pathological and virological findings of type I interferon receptor knockout mice upon experimental infection with Heartland virusHikaru Fujii, Shuetsu Fukushi, Tomoki Yoshikawa, et al.
Plos Pathogens|February 3, 2021
A highly attenuated vaccinia virus strain LC16m8-based vaccine for severe fever with thrombocytopenia syndromeTomoki Yoshikawa, Satoshi Taniguchi, Hirofumi Kato, et al.
Scientific Reports|October 22, 2024
Improved efficacy of SARS-CoV-2 isolation from COVID-19 clinical specimens using VeroE6 cells overexpressing TMPRSS2 and human ACE2Hitomi Kinoshita, Tsukasa Yamamoto, Yudai Kuroda, et al.
Antiviral Research|July 7, 2022
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2Hirofumi Ohashi, Takayuki Hishiki, Daisuke Akazawa, et al.
Pageof 6